Abstract

Tumors are hospitable environments to bacteria and several recent studies on cancer patient samples have introduced the concept of an endogenous tumor microbiome. For a variety of reasons, this putative tumor microbiome is particularly challenging to investigate, and a failure to account for the various potential pitfalls will result in erroneous results and claims. Before this potentially extremely medically-significant habitat can be accurately characterized, a clear understanding of all potential confounding factors is required, and a best-practice approach should be developed and adopted. This review summarizes all of the potential issues confounding accurate bacterial DNA sequence analysis of the putative tumor microbiome, and offers solutions based on related research with the hope of assisting in the progression of research in this field.

Highlights

  • Amplicon sequencing in bacterial microbiota studies typically targets the 16S rRNA gene subunit

  • 16S rRNA gene sequencing is still affected by the low ratio of bacterial DNA, but to a lesser extent than whole genome sequencing methods

  • The presence of damaged DNA could make methods reliant on amplicon sequence variants (ASV) generation unsuitable, as an example, SNPs arising as artifacts of the FFPE process would erroneously be recorded as different strains

Read more

Summary

RESEARCH ON THE TUMOR MICROBIOME TO DATE

The recent work characterizing the microbiomes of solid tumors is outlined in Table 1 below. Due to the challenges posed in characterizing the tumor microbiome, it is likely that some or all of the studies referenced have been negatively impacted in some way, reducing their accuracy. This caveat must be kept in mind when assessing the results, and reinforces the need for the introduction of a best practice methodology to make future research more reliable

IS THERE AN AETIOLOGICAL RELATIONSHIP BETWEEN TUMORS AND BACTERIA?
WHAT IS THE SIGNIFICANCE OF ENDOGENOUS BACTERIA RESIDING WITHIN TUMORS?
Effect on Host Immune Response
Bacterial community
Colorectal cancer
Biotransformation of Drugs
Bacteria as Therapeutic Agents
BIOLOGICAL CONSIDERATIONS
Patient Sample Logistics
Low Biomass
FFPE TISSUE AS A SOURCE OF SAMPLE TISSUE
Bacterial DNA Extraction From FFPE Samples
Detection of Microbial Communities
Fusobacteria Proteobacteria
Removal of Chimeric Reads
Removal of Contamination
Analyzing the Outputs
BEST PRACTICE
Bioinformatic Analysis
POSSIBLE IMPROVEMENTS
Findings
AUTHOR CONTRIBUTIONS
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.